OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for ...

Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of ...

Researchers have identified organized clusters of B cells in the kidneys of some diabetic kidney disease patients, linked to faster progression toward kidney failure. Using advanced spatial mapping of ...

Researchers assessed whether using bispecific antibodies targeting CD20 and CD3 would reduce efficacy or increase toxicity in patients with relapsed or refractory non-Hodgkin B-cell lymphomas ...

Ultrasensitive detection of circulating tumor DNA can improve clinical outcomes in aggressive B-cell lymphomas by identifying measurable residual disease. Defining remission is challenging due to ...

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels ...

Key market opportunities for BCMA-targeted therapies include rising multiple myeloma cases, next-gen therapy approvals, ...

ModeX Therapeutics initiates clinical trial of tetraspecific antibody for treatment of B-cell lymphomas: Weston, Massachusetts Friday, April 24, 2026, 16:00 Hrs [IST] ModeX Therap ...